vs
Side-by-side financial comparison of Walt Disney Company (The) (DIS) and Merck & Co. (MRK). Click either name above to swap in a different company.
Walt Disney Company (The) is the larger business by last-quarter revenue ($26.0B vs $16.4B, roughly 1.6× Merck & Co.). Merck & Co. runs the higher net margin — 18.1% vs 9.2%, a 8.8% gap on every dollar of revenue. On growth, Walt Disney Company (The) posted the faster year-over-year revenue change (5.2% vs 5.0%). Merck & Co. produced more free cash flow last quarter ($1.8B vs $-2.3B). Over the past eight quarters, Walt Disney Company (The)'s revenue compounded faster (8.5% CAGR vs 2.0%).
The Walt Disney Company, commonly known as simply Disney, is an American multinational mass media and entertainment conglomerate headquartered at the Walt Disney Studios complex in Burbank, California. Founded on October 16, 1923, as an animation studio by brothers Walt Disney and Roy Oliver Disney as Disney Brothers Cartoon Studio, Disney operated under the names Walt Disney Studio and Walt Disney Productions before adopting its current name in 1986.
Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada. The company is ranked fourth on the list of largest biomedical companies by revenue.
DIS vs MRK — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $26.0B | $16.4B |
| Net Profit | $2.4B | $3.0B |
| Gross Margin | — | 66.2% |
| Operating Margin | 17.7% | 20.9% |
| Net Margin | 9.2% | 18.1% |
| Revenue YoY | 5.2% | 5.0% |
| Net Profit YoY | -6.0% | -20.8% |
| EPS (diluted) | $1.34 | $1.19 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $26.0B | $16.4B | ||
| Q3 25 | $22.5B | $17.3B | ||
| Q2 25 | $23.6B | $15.8B | ||
| Q1 25 | $23.6B | $15.5B | ||
| Q4 24 | $24.7B | $15.6B | ||
| Q3 24 | $22.6B | $16.7B | ||
| Q2 24 | $23.2B | $16.1B | ||
| Q1 24 | $22.1B | $15.8B |
| Q4 25 | $2.4B | $3.0B | ||
| Q3 25 | $1.3B | $5.8B | ||
| Q2 25 | $5.3B | $4.4B | ||
| Q1 25 | $3.3B | $5.1B | ||
| Q4 24 | $2.6B | $3.7B | ||
| Q3 24 | $460.0M | $3.2B | ||
| Q2 24 | $2.6B | $5.5B | ||
| Q1 24 | $-20.0M | $4.8B |
| Q4 25 | — | 66.2% | ||
| Q3 25 | — | 77.7% | ||
| Q2 25 | — | 77.5% | ||
| Q1 25 | — | 78.0% | ||
| Q4 24 | — | 75.5% | ||
| Q3 24 | — | 75.5% | ||
| Q2 24 | — | 76.8% | ||
| Q1 24 | — | 77.6% |
| Q4 25 | 17.7% | 20.9% | ||
| Q3 25 | 15.5% | 39.0% | ||
| Q2 25 | 19.3% | 31.6% | ||
| Q1 25 | 18.8% | 38.0% | ||
| Q4 24 | 20.5% | 26.7% | ||
| Q3 24 | 16.2% | 24.6% | ||
| Q2 24 | 18.2% | 37.3% | ||
| Q1 24 | 17.4% | 35.9% |
| Q4 25 | 9.2% | 18.1% | ||
| Q3 25 | 5.8% | 33.5% | ||
| Q2 25 | 22.2% | 28.0% | ||
| Q1 25 | 13.9% | 32.7% | ||
| Q4 24 | 10.3% | 24.0% | ||
| Q3 24 | 2.0% | 19.0% | ||
| Q2 24 | 11.3% | 33.9% | ||
| Q1 24 | -0.1% | 30.2% |
| Q4 25 | $1.34 | $1.19 | ||
| Q3 25 | $0.72 | $2.32 | ||
| Q2 25 | $2.92 | $1.76 | ||
| Q1 25 | $1.81 | $2.01 | ||
| Q4 24 | $1.40 | $1.49 | ||
| Q3 24 | $0.26 | $1.24 | ||
| Q2 24 | $1.43 | $2.14 | ||
| Q1 24 | $-0.01 | $1.87 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $5.7B | $14.6B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $108.5B | $52.6B |
| Total Assets | $202.1B | $136.9B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $5.7B | $14.6B | ||
| Q3 25 | $5.7B | $18.2B | ||
| Q2 25 | $5.4B | $8.6B | ||
| Q1 25 | $5.9B | $9.2B | ||
| Q4 24 | $5.5B | $13.7B | ||
| Q3 24 | $6.0B | $14.6B | ||
| Q2 24 | $6.0B | $11.4B | ||
| Q1 24 | $6.6B | $5.6B |
| Q4 25 | — | — | ||
| Q3 25 | $42.0B | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $45.8B | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $108.5B | $52.6B | ||
| Q3 25 | $109.9B | $51.9B | ||
| Q2 25 | $109.1B | $49.0B | ||
| Q1 25 | $104.3B | $48.3B | ||
| Q4 24 | $101.9B | $46.3B | ||
| Q3 24 | $100.7B | $44.5B | ||
| Q2 24 | $100.6B | $43.6B | ||
| Q1 24 | $99.3B | $40.4B |
| Q4 25 | $202.1B | $136.9B | ||
| Q3 25 | $197.5B | $129.5B | ||
| Q2 25 | $196.6B | $117.5B | ||
| Q1 25 | $195.8B | $115.1B | ||
| Q4 24 | $197.0B | $117.1B | ||
| Q3 24 | $196.2B | $117.5B | ||
| Q2 24 | $197.8B | $112.6B | ||
| Q1 24 | $195.1B | $105.8B |
| Q4 25 | — | — | ||
| Q3 25 | 0.38× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.45× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $735.0M | $2.9B |
| Free Cash FlowOCF − Capex | $-2.3B | $1.8B |
| FCF MarginFCF / Revenue | -8.8% | 11.1% |
| Capex IntensityCapex / Revenue | 11.6% | 6.3% |
| Cash ConversionOCF / Net Profit | 0.31× | 0.96× |
| TTM Free Cash FlowTrailing 4 quarters | $7.1B | $12.4B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $735.0M | $2.9B | ||
| Q3 25 | $4.5B | $7.8B | ||
| Q2 25 | $3.7B | $3.3B | ||
| Q1 25 | $6.8B | $2.5B | ||
| Q4 24 | $3.2B | $3.5B | ||
| Q3 24 | $5.5B | $9.3B | ||
| Q2 24 | $2.6B | $5.6B | ||
| Q1 24 | $3.7B | $3.1B |
| Q4 25 | $-2.3B | $1.8B | ||
| Q3 25 | $2.6B | $6.8B | ||
| Q2 25 | $1.9B | $2.5B | ||
| Q1 25 | $4.9B | $1.2B | ||
| Q4 24 | $739.0M | $2.5B | ||
| Q3 24 | $4.0B | $8.5B | ||
| Q2 24 | $1.2B | $4.8B | ||
| Q1 24 | $2.4B | $2.2B |
| Q4 25 | -8.8% | 11.1% | ||
| Q3 25 | 11.4% | 39.6% | ||
| Q2 25 | 8.0% | 16.0% | ||
| Q1 25 | 20.7% | 7.5% | ||
| Q4 24 | 3.0% | 16.1% | ||
| Q3 24 | 17.8% | 51.1% | ||
| Q2 24 | 5.3% | 30.1% | ||
| Q1 24 | 10.9% | 14.1% |
| Q4 25 | 11.6% | 6.3% | ||
| Q3 25 | 8.5% | 5.7% | ||
| Q2 25 | 7.5% | 4.8% | ||
| Q1 25 | 7.9% | 8.6% | ||
| Q4 24 | 10.0% | 6.0% | ||
| Q3 24 | 6.6% | 4.7% | ||
| Q2 24 | 5.9% | 4.9% | ||
| Q1 24 | 5.7% | 5.5% |
| Q4 25 | 0.31× | 0.96× | ||
| Q3 25 | 3.41× | 1.35× | ||
| Q2 25 | 0.70× | 0.74× | ||
| Q1 25 | 2.06× | 0.49× | ||
| Q4 24 | 1.25× | 0.92× | ||
| Q3 24 | 12.00× | 2.94× | ||
| Q2 24 | 0.99× | 1.03× | ||
| Q1 24 | — | 0.65× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DIS
| Subscription And Affiliate Fees | $7.3B | 28% |
| Sports Segment | $4.9B | 19% |
| Sports Third Party | $4.5B | 17% |
| Products | $2.8B | 11% |
| Resortandvacations | $2.4B | 9% |
| Content Sales | $1.9B | 7% |
| Advertising | $1.8B | 7% |
| Other Revenue | $455.0M | 2% |
| License | $193.0M | 1% |
MRK
| Pharmaceuticalsegment | $8.7B | 53% |
| Keytruda | $4.9B | 30% |
| Other | $2.7B | 16% |
| Janumet | $57.0M | 0% |
| Isentress Isentress HD | $38.0M | 0% |
| Pifeltro | $25.0M | 0% |
| Belsomra | $23.0M | 0% |
| Dificid | $17.0M | 0% |
| Delstrigo | $14.0M | 0% |
| Lagevrio | $12.0M | 0% |
| Pneumovax23 | $4.0M | 0% |
